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Abstract 
Unbalanced levels of Caveolin-3 (Cav3) are involved in muscular disorders. In the present study we 
show that differentiation of immortalized myoblasts is affected by either lack or over-expression of 
Cav3. Nevertheless, depletion of Cav3 induced by delivery of the dominant-negative Cav3 (P104L) 
form elicited a more severe phenotype, characterized by the simultaneous attenuation of the Akt and 
p38 signalling network, leading to an immature cell and molecular signature. Accordingly, 
differentiation of myoblasts harbouring Cav3 (P104L) was improved by countering the reduced Akt 
and p38 signalling network via administration of IGF-1 or Trichostatin A. Furthermore, loss of 
Cav3 correlated with a deregulation of the TGF- -induced Smad2 and Erk1/2 pathways, confirming 
that Cav3 controls TGF-  signalling at the plasma membrane. Overall, these data suggest that loss 


















Caveolae and caveolins play a prominent role to regulate signal transduction [1-3]. Caveolin-3 
(Cav3) is preponderantly expressed in the skeletal muscle, contributing to proper differentiation of 
myoblasts and homeostasis of myofibers [4-6]. Through its scaffolding domain, Cav3 interacts with 
different proteins at the plasma membrane, thereby influencing their biological activity, as occurs 
for the nitric oxide synthase [7-9], Src tyrosine kinase [10,11], Alk4 and 5 receptors [12] and PI3K-
Akt kinases [13-15]. Cav3 expression must be tightly regulated, as demonstrated by the fact that 
either a deficiency or an excess cause muscular disorders. In particular, loss of Cav3 at the 
sarcolemma is a feature sign of caveolinopathies, an heterogeneous group of genetic diseases 
caused by Cav3 mutations giving rise to dominant-negative protein forms [16-20]. The missense 
Cav3 (P104L) substitution is frequently associated to the human Limb Girdle Muscular Dystrophy 
1-C (LGMD1C, OMIM #607801) [16], and its transgenic delivery causes muscular defects also in 
mice and zebrafish models [9,12,21]. In addition, even an excess of Cav3 causes of a Duchenne-like 
muscular phenotype in transgenic mice [22], definitely suggesting that Cav3 levels influence the 
muscle homeostasis. In the present study we employed immortalized murine myoblasts to analyse 
the effects of either Cav3 (P104L) or wild-type Cav3 delivery on cell fusion, a process that is 
crucial during embryonal differentiation or muscle regeneration. We found that both low and high 
Cav3 levels affect myoblast fusion. In particular, a more severe phenotype was conferred by the 
loss of Cav3, basically correlating with the attenuation of Akt and p38 activities but also with the 
perturbation of TGF-  signalling. In addition, we show that differentiation of myoblasts harbouring 
the Cav3 (P104L) form was improved by the administration of IGF-1 or Trichostatin A, two 






Materials and methods  
Materials 
All the reagents were from Sigma-Aldrich, unless differently indicated. 
Cell cultures and morphometric analysis of myotubes  
Mouse C2C12 and rat L6E9 myoblasts were maintained under standard conditions (37°C and 5% 
CO2 in humidified incubator) and cultured in a high-serum medium, consisting of high-glucose 
DMEM supplemented with 10% or 20% FBS, respectively, in the presence of 100 g/ml penicillin-
streptomycin antibiotic. To induce differentiation, 80% confluent C2C12 or L6E9 myoblasts were 
switched to a low-serum medium (termed differentiating medium, DM), consisting of DMEM 
supplemented with 2% HS or 1% FBS, respectively. To visualize myotubular structures, cells were 
fixed in methanol and stained with Giemsa reactive. An Image ProPlus software (version 6.2) was 
used to quantify the size of myotubes. The average size was calculated as the mean of 100 samples, 
as obtained by measuring 10 myotubes in 10 different fields.  
Plasmids and cell transfections 
The plasmids harbouring either the wild-type Cav3 or the Cav3 (P104L) form, under the control of 
a CMV promoter (pCAGGS vectors), were kindly provided by Ferruccio Galbiati (University of 
Pittsburgh, USA). To allow post-mitotic expression of mutant, Cav-3 (P104L) cDNA was excised 
by pCAGGS vector with EcoRI restriction enzyme (Promega) and ligated into a pGEX-KG 
plasmid; then cDNA was excised again by double digestion with SmaI and SacI (Promega), and 
eventually ligated into the pMEX vector containing a MLC promoter [25]. Transfections were 
carried out by us
instructions. To isolate antibiotic-resistant clones, C2C12 and L6E9 were cotransfected with 
pcDNA or pBabe vectors, and cultured in high-serum medium supplemented with geneticin (0.5 
mg/ml) or puromycin (1 µg/ml), respectively.  
Drug treatments 
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The pharmacological SB203580 compound (5 M) was used to inhibit p38 activity, whereas 
LY294002 (5 M, a PI3K inhibitor) was used to block Akt activity. To induce myotube 
hypertrophy, IGF-1 (50 ng/ml) was administered to myoblasts after 2 days of differentiation, in 
order to avoid hyper-proliferative effects [23]. Alternatively, myoblasts were treated with 
Trichostatin A (TSA), an inhibitor of histone deacetylases, which raises the endogenous expression 
of follistatin and enhances the size of myotubes [24]. In particular, TSA (50 nM) was administered 
to 80% confluent cells for up to 16-18 hours before addition of DM. Human recombinant TGF-  
(Peprotech) was administered to myoblasts at the dose of 5 ng/ml. 
RNA isolation and semi-quantitative RT-PCR analysis 
Total RNA was isolated by Tri-reagent method and digested with DNAse (DNA-free, Ambion). 
RNA (2 g) was reverse-transcribed in presence of 400 units of MMLV-RT (Promega) and the 
template was used for PCR amplification. The following forward (F) and reverse (R) primers (250 












Gene reporter assays were carried out by using the Promega Dual Luciferase assay system, 
bouring 
Gene Primers Sequence PCR 
Cycles 
Size 
Cav3 F R 
ACCCCAAGAACATCAATGAG 
TGCAGAAGGTGCGGATACAC 26 310 bp 
MyoD F R 
CTGCTCTGATGGCATGATGGATTAC 
AGAGCACCTGGTAAATCGGATTGG 28 343 bp 
Myf-5 F R 
AGCCCACCAGCCCCACCTC 
TTCTGCCCAGCTTTTCTTTCCTTC 30 394 bp 
Myogenin F R 
CCAGGAGCCCCACTTCTATGACGGGG 
TGATGCTGTCCACGATGGACGTAAGGG 24 590 bp 
Follistatin F R 
CTCTTCAAGTGGATGATTTTC  
ACAGTAGGCATTATTGGTCTG 30 334 bp 
GAPDH F R 
GGTGCTGAGTATGTCGTGGAGTC 
GGACTGTGGTCATGAGCCCTTCC 21 267 bp 
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the reporter gene under the control of a MCK promoter or a four MyoD responsive element (4RE) 
[26,27], in combination with the pRL-TK-Renilla luciferase control vector to correct the 
transfection efficiency. 
Antibodies 
The following primary monoclonal antibodies were used: mouse anti-Cav3 (clone 26, BD 
Transduction Laboratories), mouse anti-GM130 (BD Transduction Laboratories), rabbit anti-MyoD 
(clone M-318, Santa Cruz Biotechnology), mouse anti-Myf5 (clone C-20, Santa Cruz 
Biotechnology), mouse anti-myogenin (clone F5D, Santa Cruz Biotechnology), mouse anti-MyHC 
(Hybridoma Bank, University of Iowa), rabbit anti-cyclin D1 (clone H295, Santa Cruz 
Biotechnology), and mouse anti-alpha-tubulin (clone B-5-1-2, Sigma-Aldrich). Rabbit polyclonal 
antibodies from Cell Signaling were used to detect the phosphorylated Akt (Ser473) and p38 
(Thr180/Tyr182) and total forms. Phosphorylated (Tyr204) and total Erk1/2 forms were recognized by 
using mouse monoclonal antibodies from Santa Cruz Biotechnology.  
Western-blot analysis 
Protein concentration was calculated by bicinchoninic acid assay (Pierce). Equal amounts of protein 
samples were separated by SDS-PAGE under reducing conditions and transferred to PVDF 
membranes. Incubation with specific primary antibodies was followed by horseradish peroxidase-
conjugated secondary antibodies (Chemicon), and the immunocomplexes were visualized using 
enhanced chemiluminescence reagent (Chemicon, Cat. number 2600-5). To analyse cyclin D1, 
MyoD, Myf-5, myogenin and MyHC, myoblasts were harvested in a cold RIPA lysis buffer, 
composed by 20 mM Tris-HCl (pH 7.6), 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM NaCl, and a mix of proteases inhibitors (Roche Molecular Biochemicals). To analyse Cav3 
expression, myoblasts were harvested in a cold Triton lysis buffer, composed by 10 mM Tris-HCl 
(pH 8.0), 1% Triton X-100, 5 mM EDTA, 150 mM NaCl and a mix of proteases inhibitors. Then 
cell lysates were centrifuged (12,000 x g for 15 min at 4°C) and the Triton-insoluble cell 
membranous fractions were used for Cav3 analysis. To analyse phosphorylated and total Akt, p38 
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and Erk1/2 forms, myoblasts were harvested in a cold lysis buffer composed by 20 mM Tris-HCl 
(pH 7.4), 0.2% Triton X-100, 1 mM EDTA, 150 mM NaCl, and a mix of proteases and 
phosphatases inhibitors (0.5 mM NaF and Na3VO4).  
Immunofluorescence microscopy 
C2C12 myoblasts were cultured on 12 mm glass coverslips coated with 20 g/ml laminin (Roche). 
Then cells were fixed with paraformaldehyde for 10 min at 37°C, washed with PBS/sucrose (2%) 
and treated with an extraction buffer, composed by 20 mM Hepes (pH 7.4), 0.5% Triton X-100, 300 
mM sucrose, 3 mM MgCl2 and 50 mM NaCl. Subsequently, C2C12 were treated with 3% BSA in 
PBS for 15 min, and incubated for 2 hours in a humid atmosphere in the presence of a diluted anti-
Cav3 antibody (1:800), anti-GM130 antibody (1:500), or anti-MyHC antibody (1:200). After PBS 
washing, samples were incubated for 1 hour in the presence of a diluted anti-mouse or anti-rabbit 
CY3 conjugated secondary antibody (1:1000, Jackson Immunoresearch). Cells were visualized by 
means of a Zeiss confocal microscope (Carl Zeiss S.p.A.), with the laser set on  = 405-488-543 nm 
and the height of the scanning = 1 m. Images (512 x 512 pixels) were then reconstructed using 
LSM Image Examiner software (Carl Zeiss S.p.A.). Alternatively, fluorescent staining was 
observed under an Axiovert S100 microscope (Zeiss), and pictures were taken with a digital camera 
(SensiCam) using the Image-Pro Plus software (version 6.2).  
Statistics 
All of the data are expressed as means  S.E. Statistical significance was determined using t-









Cell fusion of immortalized myoblasts is more severely affected by loss rather than excess of 
Cav3. 
Transgenic mice harbouring inactivating Cav3 (P104L) mutation display loss of Cav3 at the 
plasmalemma and a severe muscle atrophy [9,12], whereas mice over-expressing wild-type Cav3  
form (wtCav3) undergo a Duchenne-like muscular phenotype [22], suggesting that proper levels of 
Cav3 are crucial for maintaining the muscle homeostasis. In keeping with these observations, we 
stably over-expressed either mutated or wtCav3 form in C2C12 myoblasts to analyse the effects on 
the differentiation process. Compared to control cells delivered with an empty vector, transgene 
expression produced a significant increase of both Cav3 transcripts (Fig. 1A). However, whereas 
transfection of wild-type form produced Cav3 protein accumulation, Cav3 (P104L) triggered a 
substantial loss of Cav3 (Fig. 1A). This is consistent with previous observations indicating that 
mutated Cav3 proteins display reduced protein half-life and behave with a dominant-negative 
fashion, aggregating with the wild-type forms within the Golgi apparatus, eventually causing loss of 
Cav3 at the plasma membrane [19,20]. Confocal microscopy analysis showed that an antibody for 
Cav3 marked perinuclear regions in Cav3 (P104L) myoblasts, which were positively co-stained 
with antibodies for GM130 [28], a typical Golgi marker (Fig. 1B). On the other side, Cav3 labelling 
was predominantly localized at the plasma membrane in wtCav3 over-expressing cells, although the 
staining displayed a stronger intensity compared to control myotubes (Fig. 1B). Both of these 
conditions (low Cav3 vs. high Cav3 at the plasma membrane) impaired C2C12 myoblasts 
differentiation, but besides them, the presence of Cav3 (P104L) induced a more severe phenotype, 
as determined by the analysis of MyHC expression (Fig. 1A) and the evaluation of morphological 
differentiation (Fig. 1B). In particular, the formation of myotubes was almost abolished in the 
presence of Cav3 (P104L) form (Fig. 1B and graphical panel), likely suggesting that loss of Cav3, 
more potently than overexpression, inhibits myoblast fusion. Since Cav3 expression is 
physiologically restricted to myoblasts undergoing differentiation and mature myofibers [4,5], we 
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generated a vector harbouring Cav3 (P104L) under the control of a post-mitotic MLC promoter. 
Expression of MLC-Cav3 (P104L) impaired the myoblast fusion in both immortalized C2C12 and 
L6E9 cell lines compared to control (Fig. 2A), despite less severely in comparison with CMV-Cav3 
(P104L), as evidenced by the presence of thin myotubes (Fig. 2A,B) and a residual MyHC 
expression (Fig. 2C). Taken together, these data provide evidence that loss of Cav3 at the plasma 
membrane, as induced by Cav3 (P104L) expression, severely delays the myoblast fusion.  
Cav3 (P104L) imposes an immature molecular signature, dependent on the attenuation of Akt 
and p38 signalling network. 
We investigated the molecular mechanisms underlying the defective cell fusion in myoblasts 
harbouring Cav3 (P104L) form under the control of MLC promoter. To this purpose, we first 
looked at the Akt and p38 pathways, as this signalling network is pivotally involved in the proper 
coordination of myogenic commitment [29]. Throughout a time-course differentiation, Western-blot 
analyses detected that the loss of Cav3 induced by mutant expression correlated with the decreased 
levels of phosphorylated Akt and p38 forms compared to control cells (Fig. 3A), leading to an 
altered expression pattern of the bHLH transcription factors, such as MyoD, Myf-5 and myogenin 
[30,31]. In particular, loss of Cav3 conferred a molecular signature reminiscent of an immature cell 
state [32], being characterized by the decreased levels of MyoD and myogenin and increased levels 
of Myf-5 compared to control, as further corroborated by RT-PCR analysis (Fig. 3B). As confirmed 
by the luciferase reporter assays, the ability of MyoD to transactivate a MCK promoter or a minimal 
4RE element [26,27] was effectively impaired in MLC-Cav3 (P104L) cells compared to control 
(Fig. 3C). In addition, MLC-Cav3 (P104L) myoblasts also displayed a premature cyclin D1 
disappearance compared to control (Fig. 3A), an event normally preluding to myogenic 
commitment [33], but which can also be a consequence of the PI3K/Akt pathway down-regulation 
[34,35]. Unlikely observed in the absence of Cav3, the phosphorylation of Akt and p38 kinases was 
not decreased by wtCav3 over-expression (Fig. 3D), suggesting that lack or excess of Cav3 affect 
myoblast fusion through different mechanisms. Subsequently, we aimed to establish whether the 
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pharmacological inhibition of p38 and Akt activities, as obtained by respectively administering 
SB203580 (SB) or LY294002 (LY) compounds, was sufficient to reproduce in control myoblasts 
the molecular pattern recognized in MLC-Cav3 (P104L) myoblasts. Inhibition of either pathway 
was sufficient to preclude differentiation (not shown), leading to down-regulation of MyoD 
compared to DMSO-treated cells (Fig. 4A). In the presence of SB, however, cyclin D1 remained 
elevated, being the activity of p38 required for the proper cell cycle exit [36], further contributing to 
maintain elevated Myf-5 levels in comparison with DMSO (Fig. 4A). In the presence of LY, on the 
contrary, both Myf-5 and cyclin D1 were down-regulated compared to DMSO (Fig. 4A), 
confirming that the sole inhibition of either pathway affects differentiation but leading to a different 
molecular signature. Remarkably, the simultaneous administration of both SB and LY inhibitors 
impaired differentiation of C2C12 myoblasts (Fig. 4B) and decreased the protein content of MyoD, 
cyclin D1 and myogenin, leading to sustained Myf-5 levels (Fig. 4C), thus eliciting the molecular 
signs observed in MLC-Cav3 (P104L) myoblasts. Accordingly, 4RE reporter activity was prevented 
in C2C12 myoblasts treated with SB and LY compared to DMSO, as assayed after a transient 
transfection for up to 24 hours (Fig. 4D). Overall, these results indicate that, in our established in 
vitro models, loss of Cav3 imposes a particular immature cell and molecular signature largely 
reminiscent of the simultaneous down-modulation of Akt and p38 signalling network.  
Lack of Cav3 perturbs the activation of TGF-  pathways. 
It has been shown that, at the plasma membrane, Cav3 physically interacts with type I TGF-
receptors (termed Alk4 and Alk5) to limit the activity of Smad2 pathway [12]. For this reason, 
atrophic muscles of transgenic Cav3 (P104L) mice exhibit increased Smad2 signalling [12]. TGF-  
superfamily members, such as TGF-  or myostatin, bind different specific type II TGF- receptors 
but commonly employ Alk4 or 5 receptors to activate Smad-dependent and -independent pathways, 
including Smad2, Smad 3 and Erk1/2 [37,38]. Activation of TGF- pathways exerts an inhibitory 
effect on the myoblast differentiation, causing down-regulation of the Akt pathway [39,40], loss of 
cyclin D1 [34,35], MyoD [41] and myogenin [42], which are all hallmark signs recognized in MLC-
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Cav3 (P104L) myoblasts. Thus, we investigated whether an involvement of the TGF-  pathways 
might account for the cell behaviour observed upon Cav3 loss. After 2 days of differentiation, the 
basal levels of Erk1/2 phosphorylation appeared slightly but significantly reduced in MLC- and 
CMV-Cav3 (P104L) myoblasts compared to control, whereas Smad2 and 3 phosphorylation levels 
were unchanged (Fig. 5). Administration of TGF- rapidly induced the phosphorylation of Smad2, 
Smad3 and Erk1/2 in control, while eliciting a stronger phosphorylation of Smad2, but not Smad3, 
in Cav3 (P104L) myoblasts, thus conforming previous in vivo findings [9]. Consistently, the TGF-
-induced  Erk1/2 phosphorylation was diminished in Cav3 (P104L) myoblasts compared to control 
(Fig. 5). Taken together, these data indicate that loss of Cav3 predisposes to over-activation of 
Smad2 together with down-regulation of Erk1/2 pathways exclusively in the presence of TGF-  
trigger. In addition, these data indirectly suggest that the attenuation of Akt and p38 signalling 
observed in Cav3 (P104L) myotubes likely occurs independently on the activation of TGF-  
pathway.  
Stimulation of the Akt and p38 signalling network, via administration of IGF-1 or 
Trichostatin A, improves the differentiation of myoblasts even in absence of Cav3. 
We asked whether administration of molecules normally promoting myotubes hypertrophy might 
improve the differentiation of Cav3 (P104L) myoblasts. In particular, we employed IGF-1, a growth 
factor exerting an anabolic effect on the skeletal myofibers [23], or Trichostatin A (TSA), an 
inhibitor of histone deacetylases which promotes increased cell fusion by raising the expression of 
follistatin [24]. Phase contrast pictures and immunofluorescent MyHC staining indicated that the 
treatments effectively improved the differentiation of MLC-Cav3 (P104L) myoblasts, with a more 
pronounced effect in the case of TSA treatment (Fig. 6A). Both the treatments did not significantly 
affect the number of MyHC positive (MyHC+) myotubes (Fig. 6B), rather their size (Fig. 6C). In 
MLC-Cav3 (P104L) myoblasts treated with IGF-1 or TSA, Cav3 clearly remained mislocalized to 
the Golgi apparatus and a recovery at the plasma membrane was not observed (Fig. 6A). 
Interestingly, exposure of MLC-Cav3 (P104L) myoblasts to TSA, followed by post-mitotic IGF-1 
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treatment, elicited the formation of giant myotubes, featured by an intense perinuclear Cav3  
staining (Fig. 6D), thus confirming the ability of these cells to increase their size regardless of the 
improper Cav3 localization. As evaluated at transcript levels, TSA was effectively able to raise 
follistatin expression in both MLC-Cav3 (P104L) myoblasts and control cells (Fig. 7A) [24]. In the 
presence of IGF-1 or TSA, Western-blot analyses showed that the phosphorylation of both Akt and 
p38 kinases was partially re-enabled in MLC-Cav3 (P104L) myoblasts (Fig. 7B). Thus, the 
treatments produced a rescue of MyoD and myogenin levels and elicited a gradual Myf-5 
disappearing in MLC-Cav3 (P104L) myoblasts (Fig. 7D), leading to a recovery of MyHC during 
the differentiation (Fig. 7E). Taken together, these results indicate that both IGF-1 and the histone 
deacetylase inhibitor TSA are effective to enhance differentiation in myoblasts harbouring Cav3 
(P104L) form. 
Discussion 
Cav3 represents a first-line checkpoint for the regulation of cell signalling in muscle cells [1-3]. By 
functionally interacting at the plasma membrane with several protein partners, Cav3 influences an 
array of biological functions, thus configuring as a membrane sensor. Generation of Cav3 
transgenic and knock-out animal models has clearly suggested that balanced levels of Cav3 are 
required to maintain the muscle homeostasis, as both its lack and excess compromise the integrity 
of skeletal muscle apparatus [12,15,21,22,43]. In addition, previous works have shown that loss of 
Cav3 inhibits myoblast differentiation [44,45] or causes death of cultured muscle cells [46]. In the 
present study we provide evidence that both lack and over-expression of Cav3 affect the in vitro 
process of myoblast fusion, thus confirming previous in vivo findings. Nevertheless, loss of Cav3 
induced by Cav3 (P104L) form, but not the overexpression, elicited an immature cell and molecular 
signature due to the simultaneous attenuation of both Akt and p38 MAPK pathways, the main 
signalling networks by which the autocrine/paracrine extracellular cues signal into myoblasts to 
drive to the fusion process [29, 47-50]. In support of this evidence, a previous work showed that a 
down-regulation of both Akt and p38 pathways occurs in Cav3 null myoblasts, leading to reduced 
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insulin-stimulated glucose uptake [14]. Interestingly, Cav3 synthesis increases during 
differentiation of muscle cells quite dependently on the activation of both Akt and p38 pathways 
[44,45], suggesting that its localization at the plasma membrane might further provide a positive 
loop for the regulation of this signalling network. In this perspective, Cav3 configures as a key 
player of the myoblast fusion, and, accordingly, it has been recently shown that disruption of focal 
adhesion kinase signaling impairs myoblast fusion leading to selective down-regulation of Cav3 
[51]. While a close link between Cav3 and Akt kinase activity has been already demonstrated [13-
15], the potential relationship with p38 should be taken into account, being the activation of this 
pathway pivotally involved in the process of myoblast fusion upon N-cadherin ligation and the 
subsequent recruitment of the multifunctional cell surface Cdo protein [52,53]. Another point of 
interest in this work concerned the investigation of TGF-  signalling, being this pathway involved 
in the muscular atrophy of transgenic Cav3 (P104L) mice [12]. Our results suggest that, in cultured 
myotubes, loss of Cav3 was per se not sufficient to perturb TGF-  pathways, indicating that the 
attenuation of Akt and p38 pathways occurred independently on TGF-  signalling to promote the 
failure of myogenic program. Interestingly, Cav3 (P104L) myotubes treated with TGF-  displayed 
the over-activation of Smad2 pathway together with a down-modulation of Erk1/2 pathway, 
suggesting that the combination of these events, rather than the sole over-activation of Smad2 [12], 
might contribute to affect the integrity of myofibers. Remarkably, the differentiation of Cav3 
(P104L) myotubes was improved by treatment with IGF-1 or TSA [23,24] as effect of Akt and p38 
reactivation and apparently regardless of the lack of Cav3 recovery at the plasma membrane. These 
results indicate that if Cav3 is not strictly essential for the Akt and p38 signalling, it might rather 
serve to facilitate or change the outcome of its activation, thus working as a sensor. These data also 
suggest that the contribute of molecules sustaining Akt and p38 activities might partially counter the 
damages in Cav3-deficient muscles. Finally, another interesting feature which should be taken in 
account concerns the ability of a mutated Caveolin-1 (P132L) form, the mutation ortholog to Cav3 
(P104L), to confer an immature signature to human breast cancerous cells, leading to increased 
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invasiveness and metastatic potential [54]. In keeping with these findings, we hypothesize that the 
Cav3 (P104L) form might behave with a similar fashion in skeletal muscle, imposing an immature 
cell and molecular signature by limiting the activity of Akt and p38 signalling network. 
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Myoblast fusion is more severely affected by loss rather than excess of Cav3 at the plasma 
membrane. 
C2C12 myoblasts were stably transfected with an empty vector (control) or vectors harbouring 
either Cav3 (P104L) or wild-type Cav3 (wtCav3) forms. A, after two days of differentiation, PCR 
and Western-Blot (WB) analyses detected Cav3 transcript and protein in transfected myoblasts. 
Under the same conditions, protein content of MyHC was evaluated. B, confocal microscopic 
images showing that Cav3 was mislocalized to perinuclear Golgi regions in Cav3 (P104L) 
myoblasts, as indicated by the merged staining with GM130 marker. In contrast, wtCav3 over-
expression produced a labelling predominantly localized at the plasma membrane, as observed in 
control. Bars = 100 m. Graphical panel reporting the average number of myotubes observed after 
differentiation of control and transfected myoblasts for up to day 2. Myotubes containing two or 
more nuclei were counted in ten different microscopic fields. Data are representative of two 
independent experiments. 
Figure 2 
Cav3 (P104L) expression impairs the differentiation of C2C12 and L6E9 myoblasts. 
Control and C2C12 and L6E9 myoblasts, stably transfected with MLC- or CMV-Cav3 (P104L) 
vectors, were cultured in DM for up to day 4. A, immunofluorescent staining (IF) showing that 
Cav3 properly localized at the plasma membrane in control C2C12 myotubes, whereas in 
transfected cells accumulated in perinuclear regions without reaching the plasma membrane, as 
indicated by the arrows. Under these conditions, differentiation of MLC- or CMV-Cav3 (P104L) 
myoblasts was morphologically impaired compared to control (Giemsa staining, phase contrast 
pictures). Bars = 100 m. B, the graphs report the average number of myotubes observed in control 
and Cav3 (P104L) myoblasts. Results are representative of three independent experiments. 
Significant at p<0.05 (*) or 0.01 (**) vs. control. C, Western-blot analyses of myogenin and MyHC, 
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as detected in control and Cav3 (P104L) myoblasts over a time-course differentiation. Tubulin was 
used as loading control.  
Figure 3 
Loss of Cav3, induced by Cav3 (P104L) expression, decreases the activity of Akt and p38 
signalling, conferring an immature cell and molecular signature. 
A, Western-blot analyses of Akt and p38 forms (phosphorylated vs. total), as detected in control and 
MLC-Cav3 (P104L) myoblasts over a time-course differentiation. Under the same conditions, the 
expression of different protein markers was analyzed. Tubulin was used as loading control. B, 
graphical representation of MyoD, Myf-5 and myogenin transcript levels, obtained by RT-PCR 
analysis, as detected in control and MLC-Cav3 (P104L) myoblasts over a time-course 
differentiation. GAPDH was used to normalize expression. Results are representative of three 
independent experiments. Significant at p<0.05 (*) vs. control. C, luciferase reporter assays were 
performed to evaluate the ability of MyoD to transactivate two different MyoD-responsive 
promoters, consisting of a MCK promoter or a minimal 4RE element, which were transiently 
transfected in control C2C12 and MLC-Cav3 (P104L) myoblasts for up to 24 hours in DM. The 
reporter expression was expressed as the ratio between the activity from Firefly and Renilla 
luciferase. Results are representative of three independent experiments. Significant at p<0.01 (**) 
vs. control. D, Western-blot analyses of Akt and p38 forms (phosphorylated vs. total), as detected in 
control and wtCav3-overexpressing myoblasts after 24 hours of differentiation. Tubulin was used as 
loading control. 
Figure 4 
In C2C12 myoblasts the pharmacological inhibition of both Akt and p38 pathways triggers 
the molecular signature observed in Cav3 (P104L) myoblasts. 
A, Western-blot analyses of MyoD, Myf-5 and cyclin D1, as detected in C2C12 cells cultured in 
DM and left untreated (DMSO) or treated with SB or LY for up to day 2. Tubulin was used as 
loading control. B, phase contrast pictures showing morphology of C2C12 myoblasts cultured in 
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DM in presence of DMSO (vehicle) or both 5 M SB and LY for up to day 2. Bars = 100 m. C, 
Western-blot analyses of MyoD, Myf-5, cyclin D1 and myogenin, as detected in C2C12 cells 
cultured in DM in presence of DMSO or both SB and LY inhibitors. Tubulin was used as loading 
control. D, in C2C12 cells transiently transfected with a minimal 4-RE element for up to 24 hours, 
the ability of MyoD to transactivate the luciferase reporter was prevented in presence of both SB 
and LY treatment compared to DMSO. Results are representative of three independent experiments. 
Significant at p<0.05 (*) vs. DMSO. 
Figure 5 
Lack of Cav3 perturbs the activation of TGF-  pathways. 
Western-blot analyses of Smad2, Smad3 and Erk1/2 phosphorylation, as detected in control C2C12 
and MLC- or CMV-Cav3 (P104L) myoblasts differentiated for up to day 2, and then left untreated 
or treated with 5 ng/ml TGF-  for the indicated time-points. Tubulin was used as loading control. 
Relative quantifications are graphically shown. Results are representative of three independent 
experiments. Significant at p<0.05 (*) vs. control. 
Figure 6 
IGF-1 or TSA treatments significantly improve the differentiation of MLC-Cav3 (P104L) 
myoblasts. 
Control and MLC-Cav3 (P104L) myoblasts were cultured in DM, exposed to TSA or treated with 
IGF-1 (as described in Materials and Methods). A, phase contrast pictures showing the morphology 
of control and MLC-Cav3 (P104L) myoblasts exposed to the different treatments for up to day 4. 
Under the same conditions, immunofluorescence (IF) was performed to stain MyHC and Cav3. 
Bars = 100 m. B-C, the average number and area of control and MLC-Cav3 (P104L) myotubes 
have been quantified in the absence or presence of IGF-1 and TSA. Results are representative of 
three independent experiments. Significant at p<0.05 (*) vs. DM. D, upon TSA exposure followed 
by post-mitotic treatment with IGF-1, MLC-Cav3 (P104L) myotubes developed a giant size, despite 
being evident the perinuclear accumulation of Cav3. Bars = 100 m. 
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Figure 7 
IGF-1 or TSA treatments, by enabling Akt and p38 signalling, restore the expression of 
myogenic markers in Cav3 (P104L) myotubes. 
A, follistatin levels were monitored by RT-PCR analysis in control and MLC-Cav3 (P104L) 
myoblasts, after treatment with DMSO or TSA and subsequent exposure to DM for up to 24 hours. 
GAPDH was used to normalize expression. B, Western-blot analyses of the Akt and p38 forms 
(phosphorylated vs. total), as detected in control and MLC-Cav3 (P104L) cells subjected to IGF-1 
from day 2 to day 3, or exposed to TSA. Tubulin was used as loading control. C, Western-blot 
analyses of MyoD, Myf-5 and myogenin, as detected in control and MLC-Cav3 (P104L) myoblasts 
cultured in DM, exposed to TSA or post-mitotically treated with IGF-1 for the indicated time-
points. Tubulin was used as loading control. Numbers below the panels indicate the protein 
quantification, calculated as the ratio between each band protein and the respective tubulin. D, upon 
the same treatments seen above, Western-blot analyses detected the levels of MyHC in control and 
MLC-Cav3 (P104L) myotubes after 4 days of differentiation. 
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